...CRPC) (A) 526 Johnson & Johnson (NYSE:JNJ) Siltuximab (CNTO 328) Mitoxantrone Metastatic CRPC (A) 49 Novacea Inc....
...CRPC) (A) 526 Johnson & Johnson (NYSE:JNJ) Siltuximab (CNTO 328) Mitoxantrone Metastatic CRPC (A) 49 Novacea Inc....

...advanced hepatocellular carcinoma in combination with Nexavar sorafenib from Bayer AG and Onyx Pharmaceuticals Inc. Novacea Inc....

...Pharmaceuticals Inc. ; and Amar Singh as chief commercial officer, previously chief commercial officer at Novacea Inc....

...Gene/Cell therapy Hired: John Walker as CEO and a director, formerly chairman and CEO of Novacea Inc....

...The companies completed their previously announced reverse merger (see BioCentury, Sept. 8, 2008). Novacea Inc. (NASDAQ:NOVC), South...

...a decision on the low-dose sublingual formulation of zolpidem in 4Q09. Transcept is reverse-merging with Novacea Inc....

...Ipsen has European rights to the selective xanthine oxidase inhibitor from Teijin (see B11) . Novacea...
...NDA from Transcept for Intermezzo zolpidem to treat insomnia. Transcept, which is reverse merging into Novacea...

...of the Food, Drug and Cosmetic Act. Transcept is reverse-merging with Novacea (NASDAQ:NOVC). On Tuesday, Novacea...

...a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Novacea Inc....

...pulmonary fibrosis (IPF). Shionogi has rights for fibrotic diseases in Japan, South Korea and Taiwan. Novacea...